General Callout
Nunc dolor esse suscipit eros eros ullamco dolor. Duis velaliquam sunt urna, tempuribud doming quis, laboris ultricies ultricies urna laboris. Nostrud pulvinar nostrud elit sunt ex exercitation magna tempuribud laboris ea ex nunc sed exercitation ea laboris dignissim.
Accordion
Quis harmud ea commodo voluptate dolor urna providerent tempor amet dignissim velit consectetur harmud sint doming, urna magna velit sed commodo urna sint sunt nunc. Nunc consectetur laboris harmud dolore exercitation sed magna laboris nulla velit velaliquam ultricies. Dignissim adipiscing, sed duis ultricies sint voluptate providerent nunc nisi.
Heading 1
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Heading 2
Pariatur aliquip quis doming sint eros sit nulla consectetur velit quis consectetur ea dolore quis, eros voluptate commodo quis doming sint aliquip esse tempuribud quis velit ut ut aliquip ex quis, ullamco eu in. Nisi nulla amet quis tempor tempuribud aliquip. Adipiscing nostrud eu fugiat, duis quis sunt eu, providerent sed quis pariatur velit amet dolore in.
Call to action
Esse suscipit in eros ea sed voluptate dolore, harmud nisi, dolore ultricies fugiat amet doming ut sint ut adipiscing. Sit velit velaliquam ex nunc ut voluptate
Orkambi (lumacaftor/ivacaftor)
Status:
Negotiations were not pursued
Manufacturer:
Vertex Pharmaceuticals (Canada) Incorporated
Indication:
Cystic Fibrosis, F508del CFTR mutation
Last updated February 19, 2019
Juluca (dolutegravir/rilpivirine)
Status:
Concluded with an LOI
Manufacturer:
ViiV Healthcare
Indication:
HIV-1 Infection
Last updated February 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Primary Progressive Multiple Sclerosis
Last updated February 13, 2019
Status:
Concluded with an LOI
Manufacturer:
Hoffmann-La Roche Ltd.
Indication:
Multiple Sclerosis, Relapsing
Last updated February 13, 2019
Besponsa (inotuzumab ozogamicin)
Status:
Concluded with an LOI
Manufacturer:
Pfizer Canada ULC
Indication:
Acute Lymphoblastic Leukemia (ALL)
Last updated February 6, 2019
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
Venous thromboembolism, treatment and recurrence prevention
Last updated February 5, 2019
Status:
Concluded with an LOI
Manufacturer:
Servier Canada Inc.
Indication:
Non-valvular atrial fibrillation, prevention of stroke and systemic embolism
Last updated February 5, 2019
Status:
Negotiations were not pursued
Manufacturer:
Eisai Limited
Indication:
Advanced or Metastatic Clear-cell Renal Cell Carcinoma
Last updated January 31, 2019
Status:
Concluded without agreement
Manufacturer:
Eli Lilly Canada Inc.
Indication:
Advanced Soft Tissue Sarcoma
Last updated January 31, 2019
Status:
Concluded without agreement
Manufacturer:
Novo Nordisk Canada Inc.
Indication:
Diabetes Mellitus, Type 1 & 2
Last updated January 30, 2019